Controversies in treatment of chronic obstructive pulmonary disease

The Lancet

Volumn 378, Issue 9795, 2011, Pages 1038-1047

  Rabe, Klaus F ^a,b   Wedzicha, Jadwiga A ^c  

^a UNIVERSITY OF KIEL   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; AZITHROMYCIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROMYCIN; FLUTICASONE; FORMOTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MOXIFLOXACIN; SALMETEROL; TIOTROPIUM BROMIDE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BACTERIAL COLONIZATION; BACTERIAL LOAD; BRONCHIECTASIS; BRONCHIOLITIS OBLITERANS; BRONCHITIS; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CD8+ T LYMPHOCYTE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HEART INFARCTION; HEART PROTECTION; HOSPITAL ADMISSION; HUMAN; INFECTION RISK; LONG TERM CARE; LOW DRUG DOSE; LOWER RESPIRATORY TRACT; LUNG FUNCTION; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); MORTALITY; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SMOKING; SMOKING CESSATION; SPIROMETRY; SPUTUM ANALYSIS; THORAX RADIOGRAPHY; TREATMENT DURATION;

EID: 80052708638     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61295-6     Document Type: Review

References (104)

1. R Beaglehole, D Yach Globalisation and the prevention and control of non-communicable disease: the neglected chronic diseases of adults Lancet 362 2003 903 908
2. WHO Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach http://www.who.int.ezproxy.leidenuniv.nl: 2048/gard/publications/GARD-Manual 2007 (accessed June 14, 2011).
3. SS Salvi, PJ Barnes Chronic obstructive pulmonary disease in non-smokers Lancet 374 2009 733 743
4. LM Fabbri, KF Rabe From COPD to chronic systemic inflammatory syndrome? Lancet 370 2007 797 799
5. JC Hogg, F Chu, S Utokaparch et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease N Engl J Med 350 2004 2645 2653
6. DM Mannino, E Diaz-Guzman Interpreting lung function data using 80 predicted and fixed thresholds identifies patients at increased risk of mortality Chest 2011 10.1378/chest.11-0797 published online June 9.
7. PW Jones, G Harding, P Berry, I Wiklund, WH Chen, N Kline Leidy Development and first validation of the COPD assessment test Eur Respir J 34 2009 648 654
8. BR Celli, CG Cote, JM Marin et al. The body-mass index, airflow obstruction, dyspnea and exercise capacity index in chronic obstructive pulmonary disease N Engl J Med 350 2004 1005 1012
9. MA Puhan, J Garcia-Aymerich, M Frey et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index Lancet 374 2009 704 711
10. M Cazzola, W MacNee, FJ Martinez American Thoracic Society European Respiratory Society Task Force on outcomes of COPD Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur Respir J 31 2008 416 469
11. JR Hurst, J Vestbo, A Anzueto Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators Susceptibility to exacerbation in chronic obstructive pulmonary disease N Engl J Med 363 2010 1128 1138
12. GC Donaldson, TAR Seemungal, A Bhowmik, JA Wedzicha The relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease Thorax 57 2002 847 852
13. TAR Seemungal, GC Donaldson, EA Paul, JC Bestall, DJ Jeffries, JA Wedzicha Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 157 1998 1418 1422
14. JJ Soler-Cataluna, MA Martinez-Garcia, P Roman Sanchez, E Salcedo, M Navarro, R Ochando Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease Thorax 60 2005 925 931
15. AK Johnston, DM Mannino, GW Hagan, KJ Davis, VA Kiri Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort Thorax 63 2008 599 605
16. JR Feary, LC Rodrigues, CJ Smith, RB Hubbard, JE Gibson Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care Thorax 65 2010 956 962
17. M Decramer, CB Cooper Treatment of COPD: the sooner the better? Thorax 65 2010 837 841
18. P-O Bridevaux, MW Gerbase, NM Probst-Hensch, C Schindler, J-M Gaspoz, T Rochat Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD Thorax 63 2008 768 774
19. D Ofir, P Laveneziana, KA Webb et al. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I COPD Am J Respir Crit Care Med 177 2008 622 629
20. DE O'Donnell, P Laveneziana, J Ora, KA Webb, Y-M Lam, D Ofir Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD Thorax 64 2009 216 223
21. G Johansson, A Lindberg, K Romberg et al. Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD Prim Care Respir J 17 2008 169 175
22. PM Calverley, JA Anderson, B Celli et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N Engl J Med 356 2007 775 789
23. DP Tashkin, B Celli, S Senn et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease N Engl J Med 359 2008 1543 1554
24. CR Jenkins, PW Jones, PM Calverley et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study Respir Res 10 2009 59
25. M Decramer, B Celli, S Kesten, T Lystig, S Mehra, DP Tashkin for the UPLIFT investigators Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial Lancet 374 2009 1171 1178
26. T Troosters, B Celli, T Lystig et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial Eur Respir J 36 2010 65 73
27. C Vogelmeier, B Hederer, T Glaab et al. Tiotropium versus salmeterol for the prevention of COPD exacerbations N Engl J Med 364 2011 1093 1103
28. J Bourbeau, SJ Bartlett Patient adherence in COPD Thorax 63 2008 831 838
29. J Vestbo, JA Anderson, PMA Calverley et al. Adherence to inhaled therapy, mortality and hospital admission in COPD Thorax 64 2009 939 943
30. T O'Shaughnessy, TW Ansari, NC Barnes et al. Inflammation in bronchial biopsies of subjects with chronic bronchitits: inverse relationship of CD8+ T lymphocytes with FEV1 Am J Respir Crit Care Med 155 1997 852 857
31. KL Hattotuwa, MJ Gizycki, TW Ansari et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind placebo-controlled biopsy study Am J Respir Crit Care Med 165 2002 1592 1596
32. TS Lapperre, JB Snoeck-Stroband, MM Gosman Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease Ann Intern Med 151 2009 517 527
33. NC Barnes, YS Qiu, ID Pavord SCO30005 Study Group Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease Am J Respir Crit Care Med 173 2006 736 743
34. J Bourbeau, P Christodoulopoulos, F Maltais, Y Yamauchi, R Olivenstein, Q Hamid Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial Thorax 62 2007 938 943
35. NR Anthonisen, JE Connett, RP Murray Smoking and lung function of Lung Health Study participants after 11 years Am J Respir Crit Care Med 166 2002 675 679
36. Nocturnal Oxygen Therapy Trial Group Continuous or nocturnal oxygen therapy in hypoxaemic chronic obstructive lung disease Ann Intern Med 93 1980 391 398
37. Medical Research Council Working Party Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema Lancet 317 1981 681 686
38. RD McEvoy, RJ Pierce, D Hillman et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial Thorax 64 2009 561 566
39. RA Pauwels, CG Löfdahl, LA Laitinen for The European Respiratory Society Study on Chronic Obstructive Pulmonary Disease Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease N Engl J Med 340 1999 1948 1953
40. J Vestbo, T Sørensen, P Lange, A Brix, P Torre, K Viskum Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial Lancet 353 1999 1819 1823
41. PS Burge, PMA Calverley, PW Jones et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial BMJ 320 2000 1297 1303
42. The Lung Health Study Research Group Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease N Engl J Med 343 2000 1902 1909
43. National Institute for Clinical Excellence (NICE) Chronic obstractive pulmonary disease: national clinical guideline for management of chronic obstructive pulmonary disease in adults in primary and secondary care Thorax 59 suppl 1 2004 1 232
44. KF Rabe, S Hurd, A Anzueto, PJ Barnes et al. Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary Am J Respir Crit Care Med 176 2007 532 555
45. BR Celli, NE Thomas, JA Anderson et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH Study Am J Respir Crit Care Med 178 2008 332 338
46. W Szafranski, A Cukier, A Ramirez et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Eur Respir J 21 2003 74 81
47. PM Calverley, W Boonsawat, Z Cseke et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease Eur Respir J 22 2003 912 918
48. JA Wedzicha, PMA Calverley, TA Seemungal, G Hagan, Z Ansari Stockley RA for the INSPIRE Investigators The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide Am J Respir Crit Care Med 177 2008 19 26
49. National Institute of Health and Clinical Excellence Chronic obstructive pulmonary disease (updated) http://guidance.nice.org.uk/CG101 (accessed Aug 22, 2011).
50. GT Ferguson, A Anzueto, R Fei, A Emmett, K Knobil, C Kalberg Effect of fluticasone propionate/salmeterol (250/50μg) or salmeterol (50μg) on COPD exacerbations Respir Med 102 2008 1099 1108
51. PM Calverley, RA Stockley, TA Seemungal on behalf of the INSPIRE investigators Reported pneumonia in COPD: findings from the INSPIRE study Chest 139 2011 505 512
52. DD Sin, D Tashkin, X Zhang et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data Lancet 374 2009 712 719
53. TMA Wilkinson, M Wilks, IS Patel, S Lloyd Owen, GC Donaldson, JA Wedzicha Airway bacterial colonisation and decline in lung function in COPD Am J Respir Crit Care Med 167 2003 1090 1095
54. LM Fabbri, F Luppi, B Beghe, KF Rabe Complex chronic comorbidities of COPD Eur Respir J 31 2008 204 212
55. LM Fabbri, B Beghé, A Agusti Cardiovascular mechanisms of death in severe COPD exacerbation: time of thinking and acting beyond guidelines Thorax 66 2011 745 747
56. GC Donaldson, JR Hurst, CJ Smith, RB Hubbard, JA Wedzicha Increased risk of myocardial infarction and stroke following exacerbation of COPD Chest 137 2010 1091 1097
57. TB Horwich, GC Fonarow Reverse epidemiology beyond dialysis patients: chronic heart failure, geriatrics, rheumatoid arthritis, COPD, and AIDS Semin Dial 20 2007 549 553
58. AM Kuzma, Y Meli, C Meldrum et al. Multidisciplinary care of the patient with chronic obstructive pulmonary disease Proc Am Thorac Soc 5 2008 567 571
59. F Luppi, F Franco, B Beghé, LM Fabbri Treatment of chronic obstructive pulmonary disease and its comorbidities Proc Am Thorac Soc 5 2008 848 856
60. GB Mancini, M Etminan, B Zhang, LE Levesque, JM FitzGerald, JM Brophy Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease J Am Coll Cardiol 47 2006 2554 2560
61. SE Alexeeff, AA Litonjua, D Sparrow, PS Vokonas, J Schwartz Statin use reduces decline in lung function: VA normative aging study Am J Respir Crit Care Med 176 2007 742 747
62. V Khurana, HR Bejjanki, G Caldito, MW Owens Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans Chest 131 2007 1282 1288
63. PM Ridker, FA Fonseca, J Genest et al. Baseline characteristics of participants in the Jupiter trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity c-reactive protein Am J Cardiol 100 2007 1659 1664
64. PM Ridker, E Danielson, FA Fonesca for the JUPITER Trial Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
65. MT Dransfield, SM Rowe, JE Johnson, WC Bailey, LB Gerald Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD Thorax 63 2008 301 305
66. YR van Gestel, SE Hoeks, DD Sin et al. The impact of cardioselective β-blockers on mortality in patients with COPD and atherosclerosis Am J Respir Crit Care Med 178 2008 695 700
67. SR Salpeter, TM Ormiston, EE Salpeter, PJ Poole, CJ Cates Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis Respir Med 97 2003 1094 1101
68. Y Lacasse Review: cardioselective beta blockers do not produce adverse respiratory effects in COPD Evid Based Med 11 2006 84
69. RJ Shelton, AS Rigby, JG Cleland, AL Clark Effect of a community heart failure clinic on uptake of beta blockers by patients with obstructive airways disease and heart failure Heart 92 2006 331 336
70. ME Tinetti, ST Bogardus Jr, JV Agostini Potential pitfalls of disease-specific guidelines for patients with multiple conditions N Engl J Med 351 2004 2870 2874
71. ME Tinetti, T Fried The end of the disease era Am J Med 116 2004 179 185
72. JR Erb-Downward, DL Thompson, MK Han et al. Analysis of the lung microbiome in the "healthy" smoker and in COPD PLoS One 6 2011 e16384
73. M Hilty, C Burke, H Pedro et al. Disordered microbial communities in asthmatic airways PLoS One 5 2010 e8578 10.1371/journal.pone.0008578
74. E Monso, J Ruiz, A Rosell et al. Bacterial infection in chronic obstructive airways disease: a study of stable and exacerbated patients using the protected specimen brush Am J Respir Crit Care Med 152 1995 1316 1320
75. IS Patel, TAR Seemungal, M Wilks, S Lloyd Owen, GC Donaldson, JA Wedzicha Relationship between bacterial colonisation and the frequency, character and severity of COPD exacerbations Thorax 57 2002 759 764
76. A Rosell, E Monsó, N Soler et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease Arch Intern Med 165 2005 889 891
77. AT Hill, EJ Campbell, SL Hill, DL Bayley, RA Stockley Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis Am J Med 109 2000 288 295
78. IS Patel, I Vlahos, TMA Wilkinson et al. Bronchiectasis, exacerbation indices and inflammation in COPD Am J Respir Crit Care Med 170 2004 400 407
79. T Staykova, PN Black, EE Chacko, P Poole Prophylactic antibiotic therapy for chronic bronchitis Cochrane Database Syst Rev 1 2003 CD004105.
80. S Sethi, PW Jones, MS Theron PULSE Study group Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial Respir Res 11 2010 10
81. M Miravitlles, A Marín, E Monsó et al. Efficacy of moxifloxacin in the treatment of bacterial colonisation in COPD Eur Respir J 34 2009 1066 1071
82. RA Stockley, C O'Brien, A Pye, SL Hill Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD Chest 117 2000 1638 1645
83. M Miravitlles, A Marín, E Monsó et al. Colour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary disease Respir Res 11 2010 58
84. TAR Seemungal, T Wilkinson, JR Hurst, W Perera, JA Wedzicha Effect of erythromycin on exacerbations in COPD Am J Respir Crit Care Med 178 2008 1139 1147
85. JA Wedzicha, TAR Seemungal COPD exacerbations: defining their cause and prevention Lancet 370 2007 786 796
86. TMA Wilkinson, GC Donaldson, JR Hurst, TAR Seemungal, JA Wedzicha Impact of reporting and rarely therapy on outcome of exacerbations of COPD Am J Respir Crit Care Med 169 2004 1298 1303
87. EWMA Bischoff, DH Hamd, M Sedeno et al. Effects of written action plan adherence on COPD exacerbation recovery Thorax 66 2011 26 31
88. S Sethi, N Evans, BJ Grant, TF Murphy New strains of bacteria and exacerbations of chronic obstructive pulmonary disease N Engl J Med 347 2002 465 471
89. AJ White, S Gompertz, DL Bayley et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis Thorax 58 2003 680 685
90. NR Anthonisen, J Manfreda, CP Warren et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease Ann Intern Med 106 1987 196 204
91. JMA Daniels, D Snijders, CS de Graaff, F Vlaspolder, HM Jansen, WG Boersma Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease Am J Respir Crit Care Med 181 2010 150 157
92. A Rosell, E Monsó, N Soler et al. Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice Thorax 50 1995 758 763
93. BM Roede, P Bresser, PJE Bindels et al. Antibiotic treatment is associated with a reduced risk of a subsequent exacerbation in obstructive lung disease: a historical population-based cohort Thorax 63 2008 968 973
94. R Wilson, P Jones, T Schaberg, P Arvis, I Duprat-Lomon, PP Sagnier for the MOSAIC Study Group Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis Thorax 61 2006 337 342
95. L Davies, RM Angus, PMA Calverley Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial Lancet 354 1999 456 460
96. DE Niewoehner, ML Erbland, RH Deupree et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease N Engl J Med 340 1999 1941 1947
97. WH Thompson, CP Nielson, P Carvalho, NB Charan, JJ Crowley Controlled trial of oral prednisone in outpatients with acute COPD exacerbation Am J Respir Crit Care Med 154 1996 407 412
98. F Maltais, J Ostinelli, J Bourbeau et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial Am J Respir Crit Care Med 165 2002 698 703
99. B Ställberg, O Selroos, C Vogelmeier, E Andersson, T Ekström, K Larsson Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study Respir Res 10 2009 11
100. TAR Seemungal, R Harper-Owen, A Bhowmik et al. Respiratory viruses, symptoms and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease Am J Respir Crit Care Med 164 2001 1618 1623
101. MK Han, A Agusti, PM Calverley et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD Am J Respir Crit Care Med 182 2010 598 604
102. J Vestbo, W Anderson, HO Coxson on behalf of the ECLIPSE investigators Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) Eur Respir J 31 2008 869 873
103. LM Fabbri, PM Calverley, JL Izquierdo-Alonso for the M2-127 and M2-128 study groups Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials Lancet 374 2009 695 703
104. PMA Calverley, KF Rabe, UM Goehring for the M2-124 and M2-125 study groups Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials Lancet 374 2009 685 694